Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130413 | 0.93 | KDM4E (0.67) | KDM4EMAPK1HIF1AADRA1ARECQL | |
| SCHEMBL13376980 | 0.93 | RECQL (0.61) | RECQLTSHREPHX2CASP2L3MBTL1 | |
| SCHEMBL14507335 | 0.91 | KDM4E (0.62) | KDM4EMAPK1HIF1AADRA1ARECQL | |
| SCHEMBL2771342 | 0.91 | RECQL (0.63) | RECQLTSHREPHX2CASP2L3MBTL1 | |
| SCHEMBL860790 | 0.89 | KDM4E (0.56) | KDM4EMAPK1HIF1AADRA1ARECQL | |
| SCHEMBL16620817 | 0.89 | RECQL (0.61) | RECQLTSHREPHX2CASP2L3MBTL1 | |
| SCHEMBL15399777 | 0.87 | TSHR (0.65) | RECQLTSHREPHX2CASP2L3MBTL1 | |
| SCHEMBL21695694 | 0.87 | KDM4E (0.68) | KDM4EMAPK1HIF1AADRA1ATSHR | |
| SCHEMBL23052003 | 0.86 | CASP2 (0.67) | RECQLEPHX2CASP2L3MBTL1FAAH | |
| SCHEMBL18631906 | 0.86 | TSHR (0.62) | KDM4EADRA1ARECQLTSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | NGLY1, ELOVL6, ELOVL1 | KDM4E 1796/4885MAPK1 2932/4885HIF1A 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.